Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Receives USDA Approval for Befrena , a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco Announces Investment in U.S. Manufacturing and R&D, Driven by Tax, Tariff and Regulatory Clarity
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
Elanco Announces Expansion of Credelio Quattro and Credelio Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
Elanco's Credelio Receives First Ever FDA Emergency Use Authorization against New World Screwworm in Dogs
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Fathom Announces Upsizing of Previously Announced Placement to $3.75 Million and Planned 3,000-4,000 Meter Drill Program at the Gochager Lake Project
